Brookline Capital Management Stock Recommendations and Price Targets

This is a list of recent ratings by Brookline Capital Management.

DateCompany NameActionCurrent
Price
Price
Target
RatingImpact on
Share Price
6/7/2024
SABS
SAB Biotherapeutics
Initiated Coverage$3.00 $8.00BuyLow
5/30/2024
ALRN
Aileron Therapeutics
Upgrade$3.00Strong-BuyLow
5/30/2024
FBRX
Forte Biosciences
Initiated Coverage$1.00 $4.00BuyLow
5/15/2024
DARE
Daré Bioscience
Upgrade$0.00 $3.00Hold ➝ BuyLow
4/17/2024
DARE
Daré Bioscience
Downgrade$0.00Buy ➝ HoldN/A
4/5/2024
IMUX
Immunic
Reiterated Rating$1.00 $10.00BuyLow
3/19/2024
FUSN
Fusion Pharmaceuticals
Downgrade$22.00Buy ➝ HoldN/A
3/4/2024
ATBPF
Antibe Therapeutics
Downgrade$0.00Buy ➝ HoldLow
2/28/2024
ANVS
Annovis Bio
Downgrade$6.00 $9.00Buy ➝ HoldLow
1/25/2024
OTLK
Outlook Therapeutics
Upgrade$7.00 $31.40Hold ➝ BuyLow
12/19/2023
CYCC
Cyclacel Pharmaceuticals
Downgrade$2.00Buy ➝ HoldLow
12/7/2023
HEPA
Hepion Pharmaceuticals
Downgrade$1.00Buy ➝ HoldLow
12/4/2023
ONCT
Oncternal Therapeutics
Upgrade$8.00 $40.00Hold ➝ BuyLow
11/30/2023
LNTH
Lantheus
Initiated Coverage$81.00 $100.00BuyLow
11/15/2023
SQZB
SQZ Biotechnologies
Downgrade$0.00Buy ➝ HoldLow
11/10/2023
ANVS
Annovis Bio
Reiterated Rating$6.00 $35.00BuyLow
10/30/2023
GNLX
Genelux
Upgrade$2.00Hold ➝ BuyLow
10/17/2023
EYEN
Eyenovia
Initiated Coverage$1.00 $8.00BuyLow
10/12/2023
EDSA
Edesa Biotech
Reiterated Rating$4.00 $57.00Buy ➝ BuyLow
9/6/2023
PROC
Procaps Group
Downgrade$3.00 $4.50Buy ➝ HoldLow
8/30/2023
OTLK
Outlook Therapeutics
Downgrade$7.00Buy ➝ HoldLow
8/14/2023
ATBPF
Antibe Therapeutics
Reiterated Rating$0.00BuyLow
8/11/2023
BCEL
Atreca
Downgrade$0.00Buy ➝ HoldLow
6/5/2023
BLPH
Bellerophon Therapeutics
Downgrade$0.00Buy ➝ HoldLow
4/3/2023
ONCT
Oncternal Therapeutics
Downgrade$8.00Buy ➝ HoldLow
3/9/2023
ONCT
Oncternal Therapeutics
Reiterated Rating$8.00BuyLow
2/14/2023
DARE
Daré Bioscience
Reiterated Rating$0.00BuyLow
2/13/2023
FUSN
Fusion Pharmaceuticals
Reiterated Rating$22.00BuyLow
1/31/2023
HEPA
Hepion Pharmaceuticals
Reiterated Rating$1.00BuyLow
1/20/2023
BCEL
Atreca
Reiterated Rating$0.00BuyLow
1/12/2023
ECOR
electroCore
Reiterated Rating$6.00BuyN/A
12/7/2022
CWBR
CohBar
Downgrade$1.00Buy ➝ HoldLow
11/14/2022
IMNN
Imunon
Reiterated Rating$1.00BuyLow
10/3/2022
CWBR
CohBar
Reiterated Rating$1.00BuyLow
10/3/2022
ADIL
Adial Pharmaceuticals
Reiterated Rating$1.00BuyLow
10/3/2022
LSTA
Lisata Therapeutics
Reiterated Rating$3.00BuyLow
10/3/2022
IMNN
Imunon
Reiterated Rating$1.00BuyLow
10/3/2022
DRMA
Dermata Therapeutics
Reiterated Rating$3.00BuyLow
10/3/2022
VXRT
Vaxart
Reiterated Rating$1.00BuyLow
10/3/2022
EDSA
Edesa Biotech
Reiterated Rating$4.00BuyLow
10/3/2022
MNPR
Monopar Therapeutics
Reiterated Rating$1.00BuyLow
10/3/2022
CYCC
Cyclacel Pharmaceuticals
Reiterated Rating$2.00BuyLow
10/3/2022
OTLK
Outlook Therapeutics
Reiterated Rating$7.00BuyLow
8/10/2022
ARCT
Arcturus Therapeutics
Reiterated Rating$27.00BuyLow
8/8/2022
BCEL
Atreca
Reiterated Rating$0.00BuyLow
6/30/2022
ATBPF
Antibe Therapeutics
Reiterated Rating$0.00BuyN/A
5/18/2022
VERU
Veru
Boost Price Target$1.00$29.00 ➝ $31.00Buy ➝ BuyMedium
4/4/2022
BLPH
Bellerophon Therapeutics
Lower Price Target$0.00$26.00 ➝ $19.00Low
3/10/2022
VRCA
Verrica Pharmaceuticals
Reiterated Rating$7.00BuyMedium
3/7/2022
NTLA
Intellia Therapeutics
Upgrade$24.00 $91.00Hold ➝ BuyHigh
2/14/2022
CRSP
CRISPR Therapeutics
Reiterated Rating$56.00 $143.00BuyHigh
2/14/2022
NTLA
Intellia Therapeutics
Reiterated Rating$24.00BuyLow
2/14/2022
CRBU
Caribou Biosciences
Reiterated Rating$2.00BuyMedium
2/3/2022
BCDA
BioCardia
Reiterated Rating$3.00BuyHigh
2/2/2022
FUSN
Fusion Pharmaceuticals
Reiterated Rating$22.00BuyMedium
2/1/2022
ICCM
IceCure Medical
Reiterated Rating$1.00BuyLow
1/26/2022
HEPA
Hepion Pharmaceuticals
Reiterated Rating$1.00BuyLow
1/19/2022
DARE
Daré Bioscience
Reiterated Rating$0.00BuyHigh
12/14/2021
PROC
Procaps Group
Reiterated Rating$3.00 $13.00BuyLow
10/13/2021
KYMR
Kymera Therapeutics
Reiterated Rating$31.00 $80.00BuyMedium
10/13/2021
ADIL
Adial Pharmaceuticals
Reiterated Rating$1.00 $300.00BuyHigh
9/21/2021
DRMA
Dermata Therapeutics
Reiterated Rating$3.00 $3,360.00BuyHigh
9/3/2021
FBRX
Forte Biosciences
Reiterated Rating$1.00HoldLow
8/27/2021
VERU
Veru
Reiterated Rating$1.00BuyMedium
8/24/2021
SCYX
SCYNEXIS
Reiterated Rating$2.00BuyLow
7/29/2021
BCEL
Atreca
Reiterated Rating$0.00BuyHigh